MAPK3 and cancer: Except for drugs targeting Apolipoprotein C-III mRNA, Volanesorsen, and AKCEA-APO-CIII-LRx evaluated for familial chylomicronemia syndrome, all the other 12 drugs are either licensed or under clinical investigation for cancer (n = 10 (MAPK3, PRKD1, PRKD3, and NAE1)) or autoimmune disorders (n = 2, (TNFSF12)).